The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors-Reference-Cited by-同舟云学术

The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors

Published:2017-04 Issue:3 Volume:27 Page:194-202
ISSN:1050-1738
Container-title:Trends in Cardiovascular Medicine
language:en
Short-container-title:Trends in Cardiovascular Medicine

Author:

Secrest Matthew H.,Udell Jacob A.,Filion Kristian B.

Funder

Canadian Institutes of Health Research

Drug Safety and Effectiveness Network

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference41 articles.

1. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes;Nissen;N Engl J Med,2007

2. US Food Drug Administration. Guidance for Industry: Diabetes Mellitus—Evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes; 2008 [cited 2016 November 8th]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf.

3. Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus;Koliaki;Diabetes Ther,2011

4. Cardiovascular effects of incretin-based therapies;White;Annu Rev Med,2016

5. The design and rationale of the Saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus–Thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study;Scirica;Am Heart J,2011

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biotransformation and disposition characteristics of HSK7653, a novel long‐acting dipeptidyl peptidase‐4 inhibitor for the treatment of type 2 diabetes;Diabetes, Obesity and Metabolism;2024-04-22

2. Association between sodium–glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation;Europace;2024-03-01

3. Cardiovascular Disease Risk and Risk Reduction Strategies in Diabetes Mellitus;Contemporary Cardiology;2024

4. Novel Antidiabetic Agents and Their Effects on Lipid Profile: A Single Shot for Several Cardiovascular Targets;International Journal of Molecular Sciences;2023-06-15

5. Sodium–Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study;Diabetes Care;2022-09-28